Filing Flows › Northwest Biotherapeutics (NWBO) › Q2 2026
Northwest Biotherapeutics (NWBO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
Northwest Biotherapeutics (NWBO) reported revenue of $807K for the second quarter 2026 (Q2 2026), +516% from a year earlier and +63% from the quarter before.
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $807K | +63% | +516% |
| Operating profit | −$11.6M | — | — |
| Net earnings | −$15.4M | -597% | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $807K in Q2 2026, up 516% year over year and up 63% from the previous quarter.
Operating costs exceeded revenue by $11.6M, an operating margin of -1438.0%. Total costs fell 17% while revenue rose 516%. The quarter ended with a net loss of $15.4M, after a profit of $3.1M the previous quarter. Minority interests bore $6.2M of it: to shareholders the quarter was a loss of $9.2M.
Operating cash flow was −$7.2M. Non-cash charges added back $774K of depreciation and amortization and $181K of share-based compensation. Working capital and other items added $7.3M. Capital expenditures of $198K exceeded it, leaving free cash flow of −$7.4M.
Questions
What was Northwest Biotherapeutics' revenue in the second quarter 2026?
Northwest Biotherapeutics (NWBO) reported revenue of $807K for the second quarter 2026 (Q2 2026), +516% from a year earlier and +63% from the quarter before.